International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

BMS Press Release Graphic

Bristol Myers Squibb has announced the U.S. Food and Drug Administration’s (FDA) approval of Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years. The approval follows the results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which proved the efficacy of once-daily Sotyktu compared to placebo and twice-daily Otezla® (apremilast) in achieving clearer skin. IPC Councilor April Armstrong, MD, MPH, was quoted in the press release stating, “Sotyktu has the potential to become the new standard of care oral treatment for people with moderate to severe plaque psoriasis, given its profile in helping patients achieve clearer skin as demonstrated in the POETYK PSO clinical program.”

Bristol myers squibb logo small

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Shining a Spotlight: Catching up with 2021 IPC Fellow Álvaro González-Cantero MD, PhD

Getting to Know IPC’s Board Member Andrew Blauvelt: What Inspired Me to Specialize in Psoriasis

Commentary -Tiago Torres

Commentary: Single-cell and Spatial Transcriptomics Analysis of Psoriasis Skin Lesions After IL-23 Inhibition

Also Read

Commentary -Tiago Torres
Genetic mechanisms

Commentary: Single-cell and Spatial Transcriptomics Analysis of Psoriasis Skin Lesions After IL-23 Inhibition

Gain expert insights into two recent publications shedding light on the molecular mechanisms of IL-23/IL-17 axis-targeting biologic therapies for psoriasis treatment. The commentary discusses longitudinal single-cell and spatial transcriptomics analyses, revealing early drug actions and genetic factors influencing clinical responses.

Read More
Psoriasis Research

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving understanding of psoriasis management, genetic insights, and treatment strategies presented in the Gunnar Lomholt Symposium. Access the full report on the IPC website and published in JID Innovations.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.